Valif appears in Indian medicine catalogues as a vardenafil tablet product associated with Ajanta Pharma. One well-defined listing is Valif 20, described as an oral tablet containing vardenafil 20 mg. That is a more useful starting point than broad internet claims that the brand is available in many strengths or formulations without any original evidence.
Independent India-market records attribute Valif to Ajanta Pharma, but a retailer’s company field does not settle every legal or operational role, such as trademark owner, marketer, batch manufacturer or exporter. The exact package and authoritative product documentation should be used before publishing a definitive statement about an individual manufacturer or wider product family.
This page therefore focuses on Valif 20 identity and the boundaries of available evidence. It does not promote foreign-to-U.S. purchases or substitute for FDA-approved generic vardenafil. The India-market directory covers Vilitra and Zhewitra separately.
India-market pharmacy records describe Valif 20 as a vardenafil 20 mg tablet used for erectile dysfunction. The listing is evidence for a named medicine claim in its relevant market; it does not authenticate every item carrying the name in an advertisement.
Vardenafil is a PDE5 inhibitor requiring sexual stimulation for its intended ED effect. Product identity still matters because a medicine’s actual active substance, strength, route and regulatory status cannot be inferred merely from a familiar drug-class label.
The following table intentionally favors a narrow documented product over an invented broad assortment. Search snippets may mix Valif with other vardenafil brands or describe different tablet strengths without robust supporting records.
Each assertion should remain tied to a source capable of supporting it, not to a generalized manufacturer label or overseas storefront description.
| Valif identity question | Supported or reported information | What remains to verify |
|---|---|---|
| Valif 20 active ingredient | Indian pharmacy records list vardenafil 20 mg | Original labeled pack and insert |
| Dosage form | Oral tablet in medicine listings | Product-specific finished-dose details |
| Company association | Ajanta Pharma appears in multiple retail records | Whether listed role is marketer or manufacturer |
| Additional Valif strengths | Not adequately established here | Authenticated records for each named SKU |
| Combinations or jelly | No verified Valif line established here | Do not presume they exist |
| United States status | Foreign-market record is not FDA approval | Exact U.S. application if ever claimed |
India-market retailer records and drug databases commonly attribute Valif 20 to Ajanta Pharma. The appropriate cautious editorial formulation is “Ajanta-associated” or “listed with Ajanta Pharma” unless an original market authorization or pack insert independently identifies the role.
For manufacturing specificity, check which entity is shown on the actual product’s license, label and batch information. Even a large company can have different roles across brands and markets. Avoid extrapolating a retailer’s single company field into a statement about every product that might be sold under the name.
Some marketing sources discuss possible Valif strengths beyond the separately documented 20 mg medicine record. Without consistent primary documentation, repeating those claims would create the appearance of a complete product catalogue that has not actually been verified.
An editorial page can be substantive without manufacturing artificial variants. A focused description of the labeled 20 mg claim, company attribution and regulatory boundaries is more useful than dozens of speculative product bullets. Readers needing U.S. strength comparisons should consult the approved-tablet strengths guide.
U.S. approval concerns a precise drug product, application and dosage form. An Indian pharmacy’s ingredient record—even when it names the same vardenafil molecule—does not establish that Valif has FDA approval, is therapeutically equivalent to a U.S. generic or can be lawfully dispensed by a U.S. pharmacy.
Original Levitra and Staxyn branded products were discontinued in the United States, and independent generic applications must be checked on their own. The historical brand overview and the generic guide explain those distinctions.
Valif 20’s ingredient claim identifies a tablet strength; it does not tell a reader that 20 mg is medically appropriate for them. Label-based U.S. prescribing uses individualized clinical assessment, including possible interaction-related adjustments and cardiovascular risk review.
Vardenafil is contraindicated with organic nitrates and riociguat and has particular QT-related precautions. No person should adjust an ED prescription based on a foreign product listing or combine other PDE5 inhibitors. The U.S. dosing guide covers the approved-label context.
A photograph of Valif packaging on a reseller site is not a verification of the actual medicine’s contents, its batch, supply chain or relationship with Ajanta Pharma. Different websites may reuse stock images or repeat product summaries, and some contain plainly inconsistent ingredient descriptions.
Authentic identification would use an intact pack, legible ingredients, strength, manufacturer or marketer details, batch and relevant national-market documentation. If important fields conflict, avoid relying on the listing for a treatment decision.
Valif’s foreign-market identity does not make it a routine U.S. import or mail-order alternative. Importing unapproved prescription drugs generally faces legal restrictions, and seller claims of guaranteed international shipping do not establish legality or pharmacy credentials.
For U.S. treatment, obtain professional evaluation and a valid prescription for an appropriate FDA-approved product dispensed by a licensed pharmacy. The U.S. dispensing guide explains the lawful steps and verification of sellers.
A useful and supportable statement is that Valif 20 is an India-market vardenafil 20 mg tablet listed with Ajanta Pharma in multiple pharmacy records. Claims about every possible Valif variant, exact physical manufacturer or FDA status require separate evidence and should not be embellished.
That distinction gives the page its individual research value: documented ingredient identity and company attribution presented with explicit uncertainty, rather than recycled warnings masquerading as brand-specific data.
Valif is an India-market vardenafil-associated brand; documented listings include the Valif 20 tablet.
India-market medicine records list vardenafil 20 mg per tablet. An actual pack should be checked before use.
Multiple pharmacy records connect Valif with Ajanta Pharma; the precise manufacturer versus marketer role needs primary documentation.
The documentation assessed here does not establish such a product line, so those variants should not be presumed.
Sharing a reported ingredient does not establish product-specific FDA approval or therapeutic equivalence.
No. A labeled product strength is not individualized medical advice or a starting-dose recommendation.
Do not assume lawful importation or a licensed U.S. dispensing channel for a foreign-market product.
The full product name, active ingredients, dosage form, strength, company roles, lot details and relevant marketing-market records.